B-PO05-038 IMPACT OF AGE ON PATIENT SELECTION IN LEADLESS PACEMAKER IMPLANT: EXPERIENCE WITH THE MICRA TRANSCATHETER PACEMAKER

The Micra™ leadless pacemaker was implanted with high success and a low major complication rate in both investigational trials and clinical practice. However, whether the patient profile and outcomes differ based upon patient age is not known. To describe outcomes in patients undergoing Micra implantation according to age. Patients (n=4092) from the Micra IDE and post-market global trials were included and divided into age groups: ≤40 (n=120), 41-<65 (n=424), 65-80 (n=1836), and >80 (n=1712). Baseline characteristics were summarized. A Fine-Gray competing risk model was used to compare risk for major complication through 12 months. Patients ≤40 were more often female and had fewer co-morbidities compared with older patients (Table). Among patients ≤40, the most common indication for implant was syncope (37.5%) while bradycardia with AF was the most common indication among all other age groups. Micra was successfully implanted in 4063 of 4092 patients (99.3%) and in 100% of patients ≤40 years. Median pacing percentage was lowest in the ≤40 group (n=63, median= 0.2%) and was highest in the >80 group (n=1037, median 84.4%). The major complication rate at 12 months was 2.9% and did not significantly differ across age groups (P=0.646). Micra was successfully implanted with a low rate of major complications across a broad range of age groups. Younger patients were more often implanted for indications other than AF, which may indicate that physicians consider the benefits of single chamber leadless pacing outweigh the risks associated with dual chamber transvenous pacing in this population.